A 58-year-old man with acute leukemia undergoing chemotherapy develops persistent fever (38.5°C), cough, and dyspnea. Chest X-ray shows bilateral interstitial infiltrates. Blood cultures and sputum cultures are negative. Bronchoscopy with BAL reveals Pneumocystis jirovecii. His CD4 count is 45 cells/μL. He is started on high-dose intravenous amphotericin B deoxycholate (1 mg/kg/day). On day 3 of therapy, serum creatinine rises from 1.0 to 2.8 mg/dL, and urine output drops to 400 mL/day. Which of the following is the most appropriate next step?

Explanation

## Management of Amphotericin B Nephrotoxicity in PCP ### Pathophysiology of Amphotericin B Nephrotoxicity **Key Point:** Amphotericin B deoxycholate causes dose-dependent, reversible acute tubular necrosis (ATN) through direct tubular toxicity and renal vasoconstriction. Mechanism: 1. Binds to ergosterol in fungal cell membranes → forms pores 2. Also binds to cholesterol in mammalian cell membranes (especially renal tubules) 3. Causes electrolyte wasting (K^+^, Mg^2+^) and polyuric renal failure 4. Incidence: 80% of patients develop some degree of renal impairment ### Clinical Presentation in This Patient **High-Yield:** The rise in creatinine from 1.0 to 2.8 mg/dL within 3 days, coupled with oliguria (400 mL/day), indicates **significant amphotericin B nephrotoxicity**. This requires immediate intervention. ### Optimal Management Strategy **Clinical Pearl:** When nephrotoxicity develops during amphotericin B deoxycholate therapy, the standard approach is to **switch to a lipid formulation** rather than reduce the dose, because: - Lipid formulations (amphotericin B lipid complex, liposomal amphotericin B) have **10-fold lower nephrotoxicity** - Dose reduction compromises antifungal efficacy in severe PCP (CD4 <50) - Lipid formulations achieve higher lung concentrations ### Comparison of Amphotericin B Formulations | Formulation | Nephrotoxicity | Dose (PCP) | Cost | Efficacy | |---|---|---|---|---| | Deoxycholate | High (80%) | 0.6–1 mg/kg/day | Low | Standard | | Lipid Complex | Low (10–20%) | 5 mg/kg/day | High | Superior | | Liposomal | Very low (5–10%) | 3–5 mg/kg/day | Very high | Superior | ### Supportive Measures **Key Point:** Aggressive hydration with **normal saline (0.9%)** is essential to minimize nephrotoxicity: - Maintain urine output >200 mL/hr - Avoid hypotonic fluids (cause hyponatremia) - Monitor electrolytes daily (K^+^, Mg^2+^, Na^+^) - Replace electrolytes as needed ### Why Switch, Not Reduce? ```mermaid flowchart TD A[Amphotericin B Nephrotoxicity Develops]:::outcome --> B{Action?}:::decision B -->|Reduce dose| C[Inadequate antifungal coverage]:::urgent C --> D[Treatment failure in severe PCP]:::urgent B -->|Switch to lipid formulation| E[Maintain antifungal efficacy]:::action E --> F[Reduce nephrotoxicity 10-fold]:::action F --> G[Successful PCP eradication]:::outcome ``` **High-Yield:** In **severe PCP** (CD4 <50, hypoxemia), dose reduction is contraindicated because it risks treatment failure. Switching formulations is the evidence-based approach. ### Monitoring After Switch - Renal function (creatinine, BUN) daily - Electrolytes (K^+^, Mg^2+^, Na^+^, Ca^2+^) daily - Urine output and fluid balance - Clinical response (fever, oxygenation) every 48 hours [cite:Harrison 21e Ch 212; KD Tripathi 8e Ch 51]